IP Library › Granted Patent US 12,396,956
Granted Patent B2
US 12,396,956 · App. 18/421,426 · Granted Aug 26, 2025

Modified release compositions of a gamma-hydroxybutyric acid derivative

Inventors: Sami Karaborni (Cupertino, CA); Daniel M. Canafax (Half Moon Bay, CA); Jia-Ning Xiang (Fremont, CA); William W. Xiang (Fremont, CA); James Tien (Wuhan, CN); Stefanie Thiel (Binzen, DE); Norbert Pollinger (Binzen, DE); Annette Grave (Binzen, DE)
Assignee: XWPHARMA LTD.
A61K9/2866A61K9/2009A61K9/2013A61K9/2054
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,956
App. No.
18/421,426
Granted
Aug 26, 2025
Kind
B2
Abstract

Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Claims (35)

1. A pharmaceutical composition comprising:

(a) an immediate release component, wherein the immediate release component comprises from 10 wt % to 50 wt % of 4-((L-valyl)oxy)butanoic acid; and

(b) a modified release component, wherein

the modified release component comprises modified release granules; and

the modified release component comprises from 50 wt % to 90 wt % of 4-((L-valyl)oxy)butanoic acid;

wherein wt % is based on the total weight of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.

2. The pharmaceutical composition of claim 1 , wherein a weight ratio of 4-((L-valyl)oxy)butanoic acid in the immediate release component to 4-((L-valyl)oxy)butanoic acid in the modified release component is from 1:1 to 1:4.

3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from 0.1 g to 20 g of 4-((L-valyl)oxy)butanoic acid.

4. The pharmaceutical composition of claim 1 , wherein

the immediate release component comprises from 2 g to 4 g of 4-((L-valyl)oxy)butanoic acid; and

the modified release component comprises from 8 g to 16 g of 4-((L-valyl)oxy)butanoic acid.

5. The pharmaceutical composition of claim 1 , wherein the immediate release component comprises immediate release granules comprising 4-((L-valyl)oxy)butanoic acid.

6. The pharmaceutical composition of claim 5 , wherein the immediate release granules have an average diameter from 75 μm to 450 μm, wherein the average diameter is determined by sieve analysis or by laser diffraction.

7. The pharmaceutical composition of claim 5 , wherein

the immediate release granules comprise greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the immediate release granules.

8. The pharmaceutical composition of claim 5 , wherein the immediate release granules comprise hydroxypropylmethyl cellulose and talc.

9. The pharmaceutical composition of claim 1 , wherein the modified release granules have an average diameter from 150 μm to 400 μm, wherein the average diameter is determined by sieve analysis or by laser diffraction.

10. The pharmaceutical composition of claim 1 , wherein

the modified release granules comprise a core and a modified release coating surrounding the core;

the core comprises greater than 80 wt % of 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the core.

11. The pharmaceutical composition of claim 1 , wherein

the modified release granules comprise greater than 60 wt % of the 4-((L-valyl)oxy)butanoic acid; and

wt % is based on the total weight of the modified release granules.

12. The pharmaceutical composition of claim 1 , wherein the modified release granules comprise dibutyl sebacate and talc.

13. The pharmaceutical composition of claim 1 , wherein the immediate release component comprises 4-((L-valyl)oxy)butanoic acid dissolved in a solution.

14. The pharmaceutical composition of claim 1 , wherein

the pharmaceutical composition comprises a suspension; and

the modified release component comprises the modified release granules dispersed in the suspension.

15. A kit comprising the pharmaceutical composition of claim 1 .

16. A method of treating a disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 , wherein the disease is selected from narcolepsy, excessive daytime sleepiness, cataplexy, excessive daytime sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue, fatigue associated with Parkinson's diseases, fatigue associated with multiple sclerosis, and fibromyalgia.

17. A method of treating a disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 , wherein the disease is selected from rapid eye movement sleep behavior disorder, spasmodic dystonia, symptoms of schizophrenia, insomnia, insomnia associated with schizophrenia, idiopathic hypersomnia, chronic fatigue syndrome, cluster headache, symptoms of Alzheimer's disease, symptoms of Parkinson's disease, essential tremor, posttraumatic stress syndrome, insomnia associated with posttraumatic stress syndrome, and anxiety.

18. The method of claim 16 , wherein administering comprises administering once a day dosing composition.

19. The method of claim 16 , wherein administering comprises administering twice a day dosing composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2024
From: KARABORNI, SAMI; CANAFAX, DANIEL M.; XIANG, JIA-NING; XIANG, WILLIAM W.; TIEN, JAMES; THIEL, STEFANIE; POLLINGER, NORBERT; GRAVE, ANNETTE
To: XWPHARMA LTD.
Reel/Frame 066244/0790 →
Continuity (4)
Continuation 17843097 · Jun 17, 2022
Continuation 17494749 · Oct 5, 2021
Provisional Application 63087515 · Oct 5, 2020
Related Publication 20240156741A1 · May 16, 2024
References Cited (152)
US 4843093A · Nagai et al. · 1989 [cited by applicant]
US 5594030A · Conte et al. · 1997 [cited by applicant]
US 8193211B2 · Liang et al. · 2012 [cited by applicant]
US 8529954B2 · Lebon et al. · 2013 [cited by applicant]
US 8591922B1 · Allphin et al. · 2013 [cited by applicant]
US 8598191B2 · Liang et al. · 2013 [cited by applicant]
US 8765178B2 · Parikh et al. · 2014 [cited by applicant]
US 8778398B2 · Rourke et al. · 2014 [cited by applicant]
US 10272062B2 · Megret et al. · 2019 [cited by applicant]
US 10398662B1 · Allphin et al. · 2019 [cited by applicant]
US 10457627B2 · Xiang et al. · 2019 [cited by applicant]
US 10501401B2 · Xiang et al. · 2019 [cited by applicant]
US 10640451B2 · Xiang et al. · 2020 [cited by applicant]
US 10758488B2 · Allphin et al. · 2020 [cited by applicant]
US 10774031B2 · Xiang et al. · 2020 [cited by applicant]
US 10813885B1 · Allphin et al. · 2020 [cited by applicant]
US 10959956B2 · Allphin et al. · 2021 [cited by applicant]
US 10966931B2 · Allphin et al. · 2021 [cited by applicant]
US 10987310B2 · Allphin et al. · 2021 [cited by applicant]
US 11065224B2 · Megret et al. · 2021 [cited by applicant]
US 11077079B1 · Allphin et al. · 2021 [cited by applicant]
US 11090269B1 · Allphin et al. · 2021 [cited by applicant]
US 11147782B1 · Allphin et al. · 2021 [cited by applicant]
US 11207270B2 · Allphin et al. · 2021 [cited by applicant]
US 11207276B2 · Shah et al. · 2021 [cited by applicant]
US 11395801B2 · Karaborni et al. · 2022 [cited by applicant]
US 11504347B1 · Grassot et al. · 2022 [cited by applicant]
US 11583510B1 · Grassot et al. · 2023 [cited by applicant]
US 11602512B1 · Dubow et al. · 2023 [cited by applicant]
US 11602513B1 · Dubow et al. · 2023 [cited by applicant]
US 20040092455A1 · Mamelak et al. · 2004 [cited by applicant]
US 20050220873A1 · Han et al. · 2005 [cited by applicant]
US 20060018964A1 · Combessis et al. · 2006 [cited by applicant]
US 20060210630A1 · Liang et al. · 2006 [cited by applicant]
US 20070134315A1 · Viera et al. · 2007 [cited by applicant]
US 20070190145A1 · Venkatesh et al. · 2007 [cited by applicant]
US 20070264323A1 · Shojaei et al. · 2007 [cited by applicant]
US 20080175873A1 · Zhou et al. · 2008 [cited by applicant]
US 20100029771A1 · Ameisen · 2010 [cited by applicant]
US 20100047343A1 · Haslam et al. · 2010 [cited by applicant]
US 20110111027A1 · Rourke et al. · 2011 [cited by applicant]
US 20110178068A1 · Almarsson et al. · 2011 [cited by applicant]
US 20110293729A1 · Lebon et al. · 2011 [cited by applicant]
US 20120076865A1 · Allphin et al. · 2012 [cited by applicant]
US 20120115950A1 · Mickle et al. · 2012 [cited by applicant]
US 20120122952A1 · Tung · 2012 [cited by applicant]
US 20120202879A1 · Cook et al. · 2012 [cited by applicant]
US 20120282335A1 · Venkatesh et al. · 2012 [cited by applicant]
US 20130012565A1 · Tung et al. · 2013 [cited by applicant]
US 20130143965A1 · Cook et al. · 2013 [cited by applicant]
US 20140004202A1 · Suplie et al. · 2014 [cited by applicant]
US 20140037745A1 · Liang et al. · 2014 [cited by applicant]
US 20140171505A1 · Allphin et al. · 2014 [cited by applicant]
US 20140249222A1 · Eller · 2014 [cited by applicant]
US 20140271896A1 · Shmeis et al. · 2014 [cited by applicant]
US 20150202588A1 · Allphin · 2015 [cited by applicant]
US 20150210624A1 · Tung et al. · 2015 [cited by applicant]
US 20160015662A1 · Eller · 2016 [cited by applicant]
US 20160068463A1 · Arnold et al. · 2016 [cited by applicant]
US 20180021284A1 · Megret et al. · 2018 [cited by applicant]
US 20180042855A1 · Rourke et al. · 2018 [cited by applicant]
US 20180155266A1 · Tung · 2018 [cited by applicant]
US 20180193277A1 · Suplie et al. · 2018 [cited by applicant]
US 20180318222A1 · Allphin et al. · 2018 [cited by applicant]
US 20190021997A1 · Tung · 2019 [cited by applicant]
US 20190183806A1 · Guillard · 2019 [cited by applicant]
US 20190183836A1 · Megret et al. · 2019 [cited by applicant]
US 20190263043A1 · Bhushan et al. · 2019 [cited by applicant]
US 20190269640A1 · Megret et al. · 2019 [cited by applicant]
US 20190269641A1 · Megret et al. · 2019 [cited by applicant]
US 20190282523A1 · Huang · 2019 [cited by applicant]
US 20190282532A1 · Megret et al. · 2019 [cited by applicant]
US 20200009076A1 · Patel et al. · 2020 [cited by applicant]
US 20200039917A1 · Xiang et al. · 2020 [cited by applicant]
US 20200113840A1 · Allphin et al. · 2020 [cited by applicant]
US 20200113853A1 · Allphin et al. · 2020 [cited by applicant]
US 20200197347A1 · Megret et al. · 2020 [cited by applicant]
US 20200223783A1 · Xiang et al. · 2020 [cited by applicant]
US 20200276142A1 · Grassot et al. · 2020 [cited by applicant]
US 20200330393A1 · Walsh et al. · 2020 [cited by applicant]
US 20200360293A1 · Guillard · 2020 [cited by applicant]
US 20200360319A1 · Grassot et al. · 2020 [cited by applicant]
US 20200368187A1 · Grassot et al. · 2020 [cited by applicant]
US 20210069105A1 · Jain et al. · 2021 [cited by applicant]
US 20210069136A1 · Jain et al. · 2021 [cited by applicant]
US 20210267928A1 · Megret et al. · 2021 [cited by applicant]
US 20210393529A1 · Karaborni et al. · 2021 [cited by applicant]
US 20210393537A1 · Karaborni et al. · 2021 [cited by applicant]
US 20220023247A1 · Xiang et al. · 2022 [cited by applicant]
US 20220105044A1 · Karaborni et al. · 2022 [cited by applicant]
US 20220304969A1 · Canafax et al. · 2022 [cited by applicant]
AU 2014202306B2 · 2014 [cited by applicant]
EP 635265A1 · 1995 [cited by applicant]
EP 1679076A1 · 2006 [cited by applicant]
EP 1749525A1 · 2007 [cited by applicant]
EP 2023900B1 · 2014 [cited by applicant]
EP 2566462B1 · 2020 [cited by applicant]
IN 1013MUM2005A · 2007 [cited by applicant]
IN 608CHE2015A · 2016 [cited by applicant]
TW 2017018456 · 2017 [cited by applicant]
WO 2002089775A1 · 2002 [cited by applicant]
WO 2004087169A1 · 2004 [cited by applicant]
WO 2005034923A1 · 2005 [cited by applicant]
WO 2006038226A2 · 2006 [cited by applicant]
WO 2008033351A2 · 2008 [cited by applicant]
WO 2009147681A1 · 2009 [cited by applicant]
WO 2010124046A1 · 2010 [cited by applicant]
WO 2011119839A1 · 2011 [cited by applicant]
WO 2011139271A1 · 2011 [cited by applicant]
WO 2014078014A2 · 2014 [cited by applicant]
WO 2015083129A1 · 2015 [cited by applicant]
WO 2015166473A1 · 2015 [cited by applicant]
WO 2017049470A1 · 2017 [cited by applicant]
WO 2017050259A1 · 2017 [cited by applicant]
WO 2018015563A1 · 2018 [cited by applicant]
WO 2020106735A1 · 2020 [cited by applicant]
Durig et al., Water-soluble cellulose ethers as release modulators for ethylcellulose coatings on multiparticulates, Pharmaceutical Technology Report, Annual Meeting of the American Association of Pharmaceutical Scienti… [cited by applicant]
Ahn et al., Hapten and Antibody Production for a Sensitive Immunoassay Determining a Human Urinary Metabolite of the Pyrethroid Insecticide Permethrin, [cited by applicant]
CAS No. 128321-03-9, entry dated Jul. 21, 1990, 1 page. [cited by applicant]
CAS No. 238401-16-6, entry dated Sep. 10, 1999, 21 pages. [cited by applicant]
Abdul et al., A flexible technology for modified-release drugs: Multiple-unit pellet system (MUPS), [cited by applicant]
Cameo Chemicals, Office of Response and Restoration, National Ocean Service, National Oceanic and Atmospheric Administration, United States Government, Ethyl-3-hydroxybutyrate, CAS No. 5405-14-4, accessed on Feb. 9, 201… [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/037830, mailed on Dec. 7, 2021, 18 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2021/037830, dated Dec. 13, 2022, 22 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/037909, mailed on Feb. 12, 2021, 23 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2021/037909, dated Dec. 13, 2022, 18 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/042818, mailed on Jan. 11, 2022, 14 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2021/042818, dated Jan. 24, 2023, 10 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2021/053640, mailed on Mar. 3, 2022, 13 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2021/053640, dated Mar. 28, 2023, 9 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2022/020926, mailed on Jun. 10, 2022, 11 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/350,478 mailed on Oct. 22, 2021, 19 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/350,478 mailed on Feb. 7, 2022, 19 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/350,478 mailed on Apr. 14, 2022, 10 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/737,700 mailed on Jan. 31, 2023, 19 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/737,700 mailed on Jun. 15, 2023, 18 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/350,939 mailed on Oct. 22, 2021, 6 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/350,939 mailed on Dec. 14, 2021, 7 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/350,939 mailed on Feb. 9, 2022, 8 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/687,160 mailed on Dec. 4, 2023, 12 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/383,253 mailed on Sep. 27, 2022, 14 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/383,253 mailed on Jan. 18, 2023, 11 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/383,253 mailed on Jun. 1, 2023, 11 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/494,749 mailed on Mar. 4, 2022, 12 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/494,749 mailed on Apr. 8, 2022, 10 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/494,749 mailed on Jun. 8, 2022, 9 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/843,097 mailed on Jun. 14, 2023, 9 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/698,609 mailed on May 27, 2022, 14 pages. [cited by applicant]
Final Office Action for U.S. Appl. No. 17/698,609 mailed on Jul. 18, 2022, 14 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/698,609 mailed on Oct. 14, 2022, 9 pages. [cited by applicant]
Non-final Office Action for U.S. Appl. No. 17/974,316 mailed on Sep. 28, 2023, 11 pages. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/974,316 mailed on Nov. 20, 2023, 10 pages. [cited by applicant]